Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MDVN [NASD]
Medivation, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own1.50% Shs Outstand76.33M Perf Week-0.67%
Market Cap4.42B Forward P/E24.19 EPS next Y2.40 Insider Trans22.99% Shs Float73.41M Perf Month-17.05%
Income-42.60M PEG- EPS next Q-0.09 Inst Own96.40% Short Float4.81% Perf Quarter-24.91%
Sales272.90M P/S16.20 EPS this Y-1.80% Inst Trans0.02% Short Ratio2.33 Perf Half Y9.72%
Book/sh1.02 P/B56.79 EPS next Y211.44% ROA-11.60% Target Price93.21 Perf Year7.90%
Cash/sh3.00 P/C19.33 EPS next 5Y- ROE-66.70% 52W Range44.51 - 88.20 Perf YTD-9.23%
Dividend- P/FCF- EPS past 5Y11.70% ROI-7.90% 52W High-34.32% Beta0.74
Dividend %- Quick Ratio3.70 Sales past 5Y85.00% Gross Margin- 52W Low30.15% ATR3.09
Employees370 Current Ratio3.70 Sales Q/Q159.70% Oper. Margin-8.10% RSI (14)35.57 Volatility5.48% 5.63%
OptionableYes Debt/Eq2.71 EPS Q/Q109.50% Profit Margin-15.60% Rel Volume0.50 Prev Close58.84
ShortableYes LT Debt/Eq2.71 EarningsMay 05 Payout- Avg Volume1.52M Price57.93
Recom2.00 SMA20-6.61% SMA50-17.84% SMA200-8.72% Volume750,785 Change-1.55%
16-Apr-14Initiated Canaccord Genuity Hold $60
17-Mar-14Reiterated Maxim Group Buy $92 → $112
03-Mar-14Reiterated UBS Buy $93 → $85
28-Feb-14Reiterated Maxim Group Buy $84 → $92
03-Feb-14Reiterated Chardan Capital Markets Buy $100
03-Feb-14Downgrade Needham Buy → Hold
29-Jan-14Reiterated Maxim Group Buy $75 → $84
29-Jan-14Reiterated Brean Capital Buy $72 → $100
29-Jan-14Reiterated Aegis Capital Buy $100 → $125
28-Jan-14Initiated CRT Capital Buy $88
10-Jan-14Reiterated Barclays Equal Weight $57 → $62
13-Nov-13Reiterated Maxim Group Buy $71 → $75
13-Nov-13Reiterated Barclays Equal Weight $53 → $57
28-Oct-13Reiterated Maxim Group Buy $66 → $71
18-Sep-13Initiated Chardan Capital Markets Buy $72
17-Jul-13Upgrade UBS Neutral → Buy $59 → $74
04-Mar-13Initiated Needham Buy
19-Dec-12Initiated UBS Neutral $59
04-Dec-12Initiated Barclays Equal Weight $56
15-Nov-12Reiterated Aegis Capital Buy $90 → $100
17-Apr-14 04:10PM  Medivation Appoints Patrick Machado to Board of Directors Marketwired
16-Apr-14 02:54PM  Johnson and Johnson Earnings Surprises With Blockbuster Potential at Motley Fool
08:21AM  Coverage initiated on Medivation by Canaccord Genuity Briefing.com
14-Apr-14 05:16PM  University of California files complaint against Medivation theflyonthewall.com
05:12PM  MEDIVATION, INC. Files SEC form 8-K, Other Events EDGAR Online
09:48AM  Medivation (MDVN) Marked As A Dead Cat Bounce Stock at TheStreet
07-Apr-14 11:02AM  [$$] Biotech Bull-Run Versus Bubble at Barrons.com
04-Apr-14 12:05PM  Why I Bought Exelixis at Motley Fool -5.11%
03-Apr-14 07:00AM  Astellas Announces European Regulatory Submission For XTANDI┬« (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer PR Newswire
31-Mar-14 07:43PM  Exelixis Continues On at Motley Fool +5.39%
04:59PM  After-hours buzz: GM, Humana, Medivation & more at CNBC
04:16PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:10PM  Medivation Names Rick Bierly Chief Financial Officer Marketwired
28-Mar-14 09:31AM  Exelixis Inc's Comet Fails To Dazzle at Motley Fool
26-Mar-14 07:33PM  Talk About High Clinical Trial Expectations at Motley Fool
25-Mar-14 12:50PM  Japan Approves Medivation/Astellas' Xtandi Zacks
24-Mar-14 07:53PM  1 Piece of News That Could Move Exelixis at Motley Fool
04:10PM  Astellas Announces Marketing Approval in Japan for XTANDI┬« (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment PR Newswire
21-Mar-14 02:32PM  Medivation, Inc: Fast Growing Drugs That May Become Blockbusters at Motley Fool
19-Mar-14 03:20PM  Medivation-Astellas Seek Xtandi Label Expansion Zacks
18-Mar-14 09:28AM  Todays Top Biotech Stories: Prosensa, Medivation, and Alcobra at Motley Fool
07:07AM  [$$] More Motivated for Medivation at Barrons.com
07:00AM  Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer Marketwired
17-Mar-14 08:26AM  Medivation price target raised to $112 from $92 at Maxim at theflyonthewall.com
13-Mar-14 10:56AM  The Biotech Bubble: Is It or Isn't It? at Barrons.com
10:56AM  The Biotech Bubble: Is It or Isn't It?
12-Mar-14 05:42PM  [video] Biotech can't go up forever: Pro Optionetics
05:42PM  [video] Biotech can't go up forever: Pro at CNBC
05:42PM  [video] Biotech can't go up forever: Pro
06-Mar-14 01:04PM  MEDIVATION, INC. Financials EDGAR Online Financials
04-Mar-14 06:31PM  Is Medivation Inc's Recent Pullback an Entry Opportunity? at Motley Fool
09:40AM  Dendreon Will Get Much Worse Before It Gets Better at Seeking Alpha
03-Mar-14 07:59PM  Investors Are in Love With Dendreon Corporation at Motley Fool
06:32PM  Was Medivation's Quarter a Disaster? at Motley Fool
28-Feb-14 01:31PM  Why Medivation (MDVN) Is Down Today Optionetics -14.92%
01:31PM  Why Medivation (MDVN) Is Down Today at TheStreet
01:24PM  Nasdaq stocks posting largest percentage decreases AP
01:09PM  Why Medivation, Inc. Shares Tumbled at Motley Fool
09:25AM  Ahead of the Bell: Medivation shares sink AP
08:30AM  Medivation Swings to Earnings in Q4 Zacks
08:30AM  Medivation Swings to Earnings in Q4
07:54AM  Medivation weakness a buying opportunity, says Brean Capital theflyonthewall.com
07:45AM  Zacks Investment Ideas feature highlights: Emergent Biosolutions, Horizon Pharma and Medivation Zacks
05:40AM  Medivation downgraded to Hold from Buy at Jefferies theflyonthewall.com
27-Feb-14 09:30PM  Medivation Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
04:16PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update Marketwired
07:07AM  Q4 2013 Medivation, Inc. Earnings Release - After Market Close CCBN
20-Feb-14 08:44AM  3 Biotech Stocks to Bet on this Earnings Season Zacks
18-Feb-14 11:27AM  Dendreon: The Time Is Now at Seeking Alpha
07:06AM  The Zacks Analyst Blog Highlights: Tesla Motors, Celgene, Actelion, Alexion Pharmaceuticals and Medivation Zacks
06:18AM  Why Medivation (MDVN) Could Beat Earnings Estimates Again Zacks
14-Feb-14 04:34PM  Celgene Plans Stock Split Zacks
01:40PM  Will NPS Pharma (NPSP) Miss This Earnings Season? Zacks
10-Feb-14 04:48PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
04:30PM  Medivation Announces Fourth Quarter and Year-End 2013 Financial Results Teleconference on February 27, 2014 Marketwired
07-Feb-14 02:22PM  Ram Selvaraju: A Pair Of Companies Ride The Sea Change In Cancer Therapeutics at Seeking Alpha
05-Feb-14 12:28PM  One hot sector that continues to deliver at MarketWatch
04-Feb-14 07:26AM  Can Medivation (MDVN) Run Higher on Strong Earnings Estimate Revisions? Zacks
03-Feb-14 06:38PM  Lightning Round: Alcoa, Wendy's & More at CNBC -6.09%
07:25AM  Medivation downgraded by Needham Briefing.com
01-Feb-14 08:04AM  Johnson & Johnson's 3 Fastest-Growing Businesses at Motley Fool
08:04AM  Johnson & Johnson's 3 Fastest-Growing Businesses
31-Jan-14 06:31PM  3 One-Drug Biotech Wonders: Seattle Genetics, Medivation, and Regeneron at Motley Fool
04:45PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
04:45PM  Medivation Announces Participation at Upcoming Investor Conference Marketwire
04:45PM  Medivation Announces Participation at Upcoming Investor Conference
09:07AM  AbbVie Misses on Earnings & Revs, Focus on HCV Data Zacks
06:04AM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:04AM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
30-Jan-14 01:31PM  2 Bright Biotech Stocks: Medivation, VolitionRx at Wall St. Cheat Sheet
02:29AM  Medivation (MDVN) in Focus: Stock Surges 11.2% Zacks
02:29AM  Medivation (MDVN) in Focus: Stock Surges 11.2%
29-Jan-14 04:36PM  Medivation Inc. and Astellas Up the Ante against Johnson & Johnson at Motley Fool +11.23%
04:36PM  Medivation Inc. and Astellas Up the Ante against Johnson & Johnson
03:30PM  Will Affymetrix (AFFX) Surprise This Earnings Season? Zacks
02:10PM  Why Medivation, Inc. Shares Jumped at Motley Fool
02:10PM  Why Medivation, Inc. Shares Jumped
12:50PM  Medivation Prevails in PREVAIL Study Zacks
12:50PM  Medivation Prevails in PREVAIL Study
12:20PM  Midday movers: Sotheby's, Google, Praxair & More at CNBC
12:20PM  Midday movers: Sotheby's, Google, Praxair & More
11:04AM  The Science Project to Viable Company Continuum...and Other Secrets of the Buy Side at Forbes
11:04AM  The Science Project to Viable Company Continuum...and Other Secrets of the Buy Side
10:05AM  Mover: Medivation rises on Xtandi data AP
10:05AM  Mover: Medivation rises on Xtandi data
09:55AM  [video] Cramer's Six in 60: VMW, MDVN & more at CNBC
09:32AM  Medivation's Xtandi Curves Are Kate Upton-esque: An Update at TheStreet
07:24AM  Medivation price target raised to $101 from $85 at JPMorgan theflyonthewall.com
28-Jan-14 06:33PM  Medivation Still Prevailing at Motley Fool
05:11PM  Phase 3 PREVAIL trial of enzalutamide showed significant benefits in OS at theflyonthewall.com
05:02PM  Medivation to Host Teleconference on January 30, 2014 to Discuss Final Results From the Phase 3 PREVAIL Trial Marketwired
05:01PM  Medivation prostate cancer drug impresses in pre-chemo study Reuters
05:01PM  Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide in Men With Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy Marketwired
08:20AM  Coverage initiated on Medivation by CRT Capital Briefing.com
22-Jan-14 06:34PM  Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation at Motley Fool
06:34PM  Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation
11:00AM  Orphan Drug Status for Alexion's Solaris Zacks
18-Jan-14 03:36PM  Bayer's Challenge in 2014? For Xofigo to Win Share From Johnson & Johnson's Zytiga at Motley Fool
17-Jan-14 06:30PM  3 Reasons Exelixis Could Excel in 2014 at Motley Fool
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Machado Clarence PatrickChief Business Officer and CFOFeb 18Option Exercise10.5940,000423,40070,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Sale82.7940,0003,311,64630,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Option Exercise10.5940,000423,40070,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Sale80.8340,0003,233,12130,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Option Exercise10.5940,000423,40070,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Sale73.4640,0002,938,57430,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Option Exercise10.5940,000423,40070,830Jan 29 07:33 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Sale75.4340,0003,017,12230,830Jan 29 07:33 PM
Hung DavidPresident and CEOJan 27Option Exercise5.88150,000882,0001,100,204Jan 28 05:39 PM
Hung DavidPresident and CEOJan 27Sale73.50150,00011,025,357950,204Jan 28 05:39 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Option Exercise10.5940,000423,40070,830Jan 23 07:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Sale76.2940,0003,051,62730,830Jan 23 07:24 PM
Rhodes Jennifer JGC & Chief Compliance OfficerJan 21Sale76.2814,0001,067,9496,000Jan 23 07:23 PM